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Abstract: Botulinum and tetanus neurotoxins are the most toxic substances known and form the 17 
growing family of clostridial neurotoxins (CNTs). They are composed of a metalloprotease light 18 
chain (L), linked via a disulfide bond to a heavy chain (H). H mediates binding to nerve terminals 19 
and the membrane translocation of L into the cytosol where their substrates, the three SNARE 20 
proteins, are localized. L translocation is accompanied by unfolding and L has to be reduced and 21 
reacquire the native fold to exert its neurotoxicity. The Thioredoxin reductase-Thioredoxin system 22 
is responsible for the reduction, but it is unknown whether the refolding of L is spontaneous or 23 
aided by host chaperones. Here we report that geldanamycin, a specific inhibitor of Hsp90, 24 
hampers the refolding of L after membrane translocation and completely prevents the cleavage of 25 
SNAREs. We also found that the effect of geldanamycin strongly synergises with that of PX-12, an 26 
inhibitor of thioredoxin, suggesting that the processes of L chain refolding and interchain 27 
disulphide reduction are strictly coupled. Indeed we found that Hsp90 and the Thioredoxin 28 
reductase-Thioredoxin system physically interact on synaptic vesicle where they orchestrate a 29 
chaperone-redox machinery which is exploited by CNTs to deliver their catalytic part in the 30 
cytosol. 31 
Keywords: botulinum neurotoxins; tetanus neurotoxin; heat shock protein 90; geldanamycin; 32 
PX-12; neuroexocytosis; synaptic vesicles; 33 
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 34 
1. Introduction 35 
The seven serotypes of botulinum neurotoxins (BoNTs), which include a very large number of 36 
sub-types [1], form with tetanus neurotoxin (TeNT) the family of clostridial neurotoxins (CNTs) [2]. 37 
BoNTs are the etiological agents of botulism, a neuroparalytic syndrome whose major symptom is 38 
an extended flaccid paralysis [3] whilst TeNT causes tetanus, a disease characterised by spastic 39 
paralysis which still is a major cause of death in non-vaccinated populations [4]. BoNTs and TeNT 40 
are very similar toxins, both from a structural and biochemical point of view, and their opposite 41 
clinical manifestations are due to their divergent journey inside the host [5, 6]. Indeed, the main 42 
BoNTs site of action is the neuromuscular junction where they block the release of acetylcholine, 43 
whilst TeNT reaches the spinal cord via retroaxonal transport and prevents the release of inhibitory 44 
neurotransmitters [4, 6, 7].  45 
CNTs are the deadliest substances known with lethal doses ranging in the order of few ng/kg 46 
[8]. Such a toxicity is ascribed to potency and specificity, two properties that are the final result of an 47 
efficient molecular architecture evolutionary shaped to exploit essential processes of vertebrates 48 
nervous system physiology [9]. CNTs structure is composed by a catalytic light chain (L, 50 kDa) 49 
that is disulphide-linked to a heavy chain (H, 100 kDa), which is responsible for neurospecific 50 
binding and delivery of L into nerve terminals [10-12]. The C-terminal part of the H chain (HC) 51 
mediates the binding to peripheral nerve terminals [2, 13-15] and the ensuing trafficking within 52 
specific vesicles which provide either the tropism of BoNTs for the neuromuscular junction [16] or 53 
the retrograde axonal transport of TeNT toward the spinal cord [4, 7, 17]. The N-terminal part of H 54 
(HN) mediates the translocation of L across the membrane of the endocytic organelles [18-22]. L is a 55 
metalloprotease which specifically cleaves one of the SNARE proteins that form the core of the 56 
neuroexocytosis nanomachine [23, 24]: the L of BoNT/A and /E targets SNAP-25 [25-28], that of 57 
BoNT/B, /D, /F, /G and TeNT removes the largest part of the cytosolic domain of VAMP-1/2 [27, 58 
29-32] whilst the L chain of BoNT/C is the sole having more than one substrates, i.e. SNAP-25 and 59 
some isoforms of Syntaxins [33, 34]. 60 
CNT’s mechanism of nerve intoxication consists of 5 main steps [35] i) binding to nerve 61 
terminals, ii) internalisation within endocytic compartments, iii) low-pH induced translocation of L, 62 
iv) cytosolic reduction of the interchain disulphide bond and v) proteolysis of SNAREs. Among 63 
these several steps, the molecular mechanism underlying the translocation of the enzymatic domain 64 
into neuronal cytosol is the least understood [22], though it is long known that the process is 65 
initiated when the organelles exploited for internalization becomes acidic [36, 37]. HN and L 66 
undergo a concerted structural change that mediates the passage of the enzymatic domain across the 67 
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membrane with the formation of an ion-conducting channel [2, 21, 22, 38]. It is not clear if channel 68 
formation is a prerequisite or a consequence of translocation [22], but it is reported that L has to 69 
undergo partial unfolding in order to cross the membrane, otherwise the translocation is abortive 70 
[20]. In fact, cargo proteins, which do not unfold at low pH attached to the amino terminus of 71 
BoNTs, drastically reduce the delivery of the L into cell cytosol [39]. As a result of its unfolding, once 72 
it has reached the cytosolic face of the membrane, the L chain has to reacquire the native structure in 73 
order to cleave its substrates. It is presently unknown whether this process is spontaneous or it is 74 
assisted by host chaperone proteins, which normally reside on the organelle membrane [40]. 75 
The involvement of host chaperones such as heat shock protein 90 (Hsp90), peptidyl prolyl 76 
cis/trans isomerases (PPIases) and protein disulphide isomerase (DPI) in the entry of several plant 77 
and bacterial exotoxins into the cytosol has been widely documented [41-48]. 78 
Recently, we found that the Thioredoxin Reductase-thioredoxin system (TrxR-Trx) is 79 
responsible for the cytosolic reduction of BoNTs and TeNT interchain disulphide bond [35, 49-51], a 80 
molecular event, which is necessary to terminate the translocation step [20, 21, 38] and enable the 81 
metalloprotease activity [26, 27, 31]. Since TrxR and Hsp90 were previously found to be fundamental 82 
in mediating both the refolding and the release of diphtheria toxin catalytic subunit [42], in the 83 
present study, we have tested the possible involvement of this cytosolic chaperone also in the uptake 84 
of CNTs enzymatic domain inside neurons. Using geldanamycin (GA), a specific and potent 85 
inhibitor of Hsp90, we found that this drug prevents CNTs toxicity in primary cell culture. We 86 
demonstrate that GA interferes with the translocation process, most likely by inhibiting the cytosolic 87 
refolding of L, but not with the other essential steps of CNTs mechanism of intoxication. Moreover, 88 
by blocking at the same time Hsp90 and the TrxR-Trx system, we observed a strong synergistic 89 
inhibitory effect indicating a combined action of these systems in the entry of the L chain into the 90 
cytosol. 91 
2. Results 92 
2.1. Hsp90 pharmacological inhibition protects primary neurons from CNTs intoxication 93 
The involvement of Hsp90 in the uptake of several bacterial toxins was suggested by 94 
pharmacological studies using specific inhibitors [41]. The most specific one, geldanamycin (GA) is a 95 
benzoquinone antibiotic that binds the ATP-binding pocket of Hsp90 thereby inhibiting its 96 
chaperone activity thus allowing the degradation of its client proteins [52]. To test the possible 97 
involvement of Hsp90 in CNTs entry, we treated primary cerebellar granule neurons (CGNs) either 98 
with BoNTs or TeNT in the presence of GA and we evaluated their toxicity by using two 99 
complementary read-outs: Western blotting (WB) and immunofluorescence (IF) (Figure 1-2). We 100 
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started with BoNT/A, which is the most common cause of human botulism [3] and the one almost 101 
invariably used in human therapy [53-55]. As expected, when BoNT/A is added to neurons, it 102 
cleaves SNAP-25, as assessed by the appearance in WB of its truncated form (SNAP-25A), detected 103 
with a specific antibody (Figure 1A, lane PC). The same result is evident also via IF analysis (Figure 104 
1B, middle panel). It is worth to note that the amount of BoNT/A used causes the almost complete 105 
cleavage of SNAP-25, as determined with an antibody that recognizes both the intact and the 106 
cleaved form of SNAP-25 (Figure S1). Whatever the read-out used, addition of GA significantly 107 
protects neurons from BoNT/A. The inhibition is concentration-dependent and complete at 12.5 µM, 108 
as indicated by the absence of SNAP-25A in WB (Figure 1A and Figure S1) and IF (Figure 1B, 109 
compare middle with right panel). As Hsp90 is involved in multiple aspects of cell physiology [56], 110 
GA is highly toxic. Accordingly, the experiment was conducted by pretreating CGNs with GA for 30 111 
minutes and concluded within 4 hours after toxin addition (see M&M) to avoid the toxicity of the 112 
drug that develops with longer incubation times (not shown); under the experimental conditions 113 
used here cell viability was not significantly affected (Figure S2).  114 
115 
Figure 1. Geldanamycin abolishes SNAP-25 cleavage in neurons treated with BoNT/A. (A) CGNs 116 
were pretreated for 30 minutes with the indicated concentrations of GA at 37 °C; then BoNT/A was 117 
added (2.5 nM final concentration) and the incubation prolonged for 3.5 hours. Thereafter, neurons 118 
were lysed and the cleavage of SNAP-25 estimated with a specific antibody against the BoNT/A 119 
truncated form. VAMP-2 and Syntaxin 1A were used as loading controls. A typical immunoblot is 120 
reported on the left, while the right panel shows the quantification of cleaved SNAP-25 as a ratio to 121 
Syntaxin 1A, taking the value in non-treated cells (NC) as 100%. SD values derive from at least three 122 
independent experiments performed in triplicates. (B) Neurons were treated as described in A, but 123 
the experiment was stopped by fixation and the presence of SNAP-25A evaluated via IF, using an 124 
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antibody specific for the BoNT/A truncated form. All the images are representative of three 125 
independent experiments. 126 
We extended our investigations to other members of CNTs family, the serotype D of BoNT 127 
(BoNT/D), a major cause of animal botulism [57] and TeNT, which is the sole responsible of tetanus. 128 
We choose these CNTs because, at variance from BoNT/A which acts on SNAP-25, they cleave 129 
VAMP-1/2 and at two different peptide bonds [27, 31]. Figures 2A and 2C show that these two toxins 130 
cause the complete disappearance of VAMP-2 staining and that the addition of GA caused a 131 
remarkable and concentration-dependent protection from the intoxication (Figure 2A and Figure 132 
2C). Consistently, IF analysis (Figure 2B and Figure 2D) shows that these two neurotoxins cause in 133 
CGNs a clear decrease of VAMP-2 (middle panels) that is prevented by treating neurons with GA 134 
(right panels).  135 
Taken together, these data clearly indicate that, despite the different protein receptors and 136 
intracellular substrates, the inhibition of Hsp90 prevents the entry of enzymatically active L chains 137 
of different CNTs into the host cell cytosol and the ensuing cleavage of their respective cytosolic 138 
substrates. 139 
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 140 
Figure 2. Geldanamycin abolishes the cleavage of VAMP-2 in neurons intoxicated with BoNT/D and 141 
TeNT. CGNs were treated like in Figure 1 using BoNT/D (A-B, 0.01 nM final concentration) or TeNT 142 
(C-D, 0.5 nM final concentration). BoNT/D was added as a pulse of 15 minutes after which culture 143 
medium with the same concentration of GA was restored for further 3.5 hours. Thereafter, neurons 144 
were lysed and the VAMP-2 content estimated with an antibody, which recognizes the intact form of 145 
the protein. SNAP-25 and Syntaxin 1A were used as loading controls. Panels on the left reports 146 
typical immunoblots while panels on the right show the quantification of residual VAMP-2 reported 147 
as a ratio to Syntaxin 1A, taking the value of non-treated cells (NC) as 100%. SD values derive from 148 
three independent experiments performed at least in triplicates. (B-D) CGNs were treated as in A 149 
and B but the experiment was stopped by fixation and evaluated by immunofluorescence using an 150 
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antibody, which detect only the intact form of VAMP-2. All the images are representative of three 151 
independent sets of experiments. 152 
The involvement of molecular chaperones different from Hsp90 in membrane translocation of 153 
several exotoxins was previously suggested [44, 46, 58, 59]. Accordingly, we took advantage by the 154 
existence of specific inhibitors such as cyclosporine A (CsA) which specifically targets Cyclophilin A 155 
[60], and VER-155008, a general inhibitor of the ATPase activity of Hsp70s [61] to test the possible 156 
role in CNTs toxicity of these chaperones. We also synthetized an Acridizinium derivative, dubbed 157 
“compound 2”, which potently inhibits Hsc70 [59], the constitutively expressed isoform of Hsp70. 158 
Remarkably, none of these molecules impacted on the cleavage of SNAP-25 by BoNT/A (Figure S3), 159 
or of VAMP-2 by BoNT/D and TeNT (not shown), strongly suggesting the primary role of Hsp90 in 160 
supporting CNTs toxicity. 161 
2.2. Geldanamycin inhibits the L chain refolding after its pH-dependent membrane translocation 162 
The remarkable inhibitory activity of GA on BoNT/A, BoNT/D and TeNT cleavage of their 163 
SNARE substrates called for a study of the effect of this drug on the various steps of their 164 
mechanism of action in order to identify which of them is affected.  165 
First, we investigated whether the inhibition of Hsp90 prevents the binding of CNTs to CGNs 166 
plasma membrane and their subsequent internalization into endosomal compartments. Neurons 167 
were pretreated either with the vehicle or with GA at a concentration causing the complete 168 
inhibition of BoNT/A activity. CGNs were then incubated for 30 minutes with the BoNT/A binding 169 
domain fused to circularly permutated Venus (cpV-HC/A), used as reporter for WB analysis. Figure 170 
3A shows that binding and internalization of cPV-HC/A were not affected by GA. The same 171 
experiment was repeated using as a reporter an antibody against the lumenal portion of the SV 172 
integral membrane protein synaptotagmin-1, to check synaptic vesicles (SVs) dynamics [62] upon 173 
GA treatment. Figure S4 shows that in control condition the antibody is incorporated through SVs 174 
cycle and can be detected by WB (lane vehicle). On the contrary, when treated with BoNT/D, which 175 
prevents the assembly of a functional SNARE complex and therefore blocks SVs dynamics, CGNs do 176 
not take up the antibody (lane BoNT/D). In GA-treated neurons the amount of internalized antibody 177 
was comparable to that of vehicle-treated neurons (lane GA), suggesting that the trafficking of the 178 
organelles used by BoNT/A [16, 63, 64], TeNT [65] and possibly BoNT/D for internalization within 179 
nerve terminals is not altered by the drug. These two complementary approaches therefore indicate 180 
that Hsp90 inhibition does not affect toxin binding and endocytosis in cultured neurons.  181 
Next, we investigated the effect of GA on endosomes acidification, which is strictly required for 182 
the membrane translocation of all CNTs [2, 66]. We used Lysotracker Red DND-99, a sensitive dye 183 
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which labels and tracks acidic organelles in living cells. Figure 3B shows that GA does not interfere 184 
with organelle acidification at variance from bafilomycin A1, which is a specific inhibitor of the 185 
vacuolar H+-ATPases [67], and is used here as positive control. 186 
Finally, Figure 3C shows that GA does not interfere with the metalloproteolytic activity of 187 
CNTs on SNAREs, using BoNT/D cleavage on VAMP-2 as an example. Similar results were obtained 188 
with BoNT/A and TeNT using their respective substrates (data not shown). 189 
 190 
Figure 3. Geldanamycin has no effect on CNTs binding, endosome acidification and in vitro 191 
metalloprotease activity. (A) CGNs were pretreated with geldanamycin (GA, 12.5 μM) or vehicle 192 
(DMSO) at 37 °C for 30 minute after which, cpV-HC/A (250 nM final concentration) was added in 193 
high K+ buffer for further 30 minutes. Neurons were then washed, lysed and the cpV-HC/A amount 194 
was estimated by WB with an antibody against GFP. Syntaxin 1A, SNAP-25 and VAMP-2 are used 195 
as loading controls. In the first lane (input) 50 ng of the cpV-HC/A were loaded as reference. The 196 
immunoblot is representative of three independent sets of experiments. (B) CGNs were treated with 197 
vehicle (DMSO) or 12.5 μM of GA or 50 nM bafilomycin A1 for 30 minutes at 37 °C. Then, 198 
Lysotracker Red was added for 1 hour and neurons were imaged by fluorescence microscopy. 199 
Images are representative of two independent experiments. (C) BoNT/D (100 ng) was reduced with 200 
10 mM DTT in the presence of 12.5 μM GA or vehicle (DMSO) for 30 minutes at 37 °C before adding 201 
1 μg of GST-VAMP-2. The reaction was carried out for 4 hours at 37 °C. VAMP-2 cleavage was 202 
assessed by SDS-PAGE. A representative image is shown. 203 
Taken together the previous results reinforce the suggestion that Hsp90 might be involved in 204 
assisting and promoting the metalloprotease L chain to reacquire its enzymatically active form after 205 
its translocation into the cytosol. If this is the case, GA is expected to impact directly on the 206 
translocation process. To test this idea, we took advantage of an intoxication method, dubbed “pH 207 
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jump”, which induces the entry of L from the plasma membrane [68-70]. As shown in Figure 4, by 208 
lowering the pH to 4.5, BoNT/D L chain is productively translocated across the plasma membrane of 209 
CGNs and delivered into the cytosol in its active form, as indicated by the cleavage of VAMP-2 (lane 210 
“4.5”). The assay is amenable to manipulation, indeed the delivery of the L chain, and the ensuing 211 
cleavage of VAMP-2, can be prevented by PX-12 (lane PX-12), a known inhibitor of Trx [71] which 212 
blocks the release of the metalloprotease in the cytosol by interfering with the reduction of the 213 
interchain disulphide bridge [49, 50]. Accordingly, the absence of VAMP-2 cleavage upon treatment 214 
with GA (lane GA), suggests that this drug directly impacts on the translocation, likely on the L 215 
chain refolding. 216 
 217 
Figure 4. PX-12 and geldanamycin inhibit L translocation across the membrane. CGNs were treated 218 
with 25 µM of PX-12 or 12. 5 µM GA for 30 min at 37 °C. Thereafter, BoNT/D (200 pM) was added in 219 
the cold for 15 minutes. Neurons were then washed and incubated for 10 min with medium A 220 
buffered at indicated pH at 37 °C supplemented with inhibitors or vehicle. Then, cells were washed 221 
and incubated for 3.25 hours in complete medium containing 50 nM bafilomycin. The translocation 222 
of BoNT/D was assessed by monitoring the cleavage of VAMP-2, determined via Western blot as a 223 
ratio to Syntaxin 1A which served as internal control, taking the value at pH 7.4 as 100%. SD values 224 
derive from three independent experiments performed in triplicates.  225 
2.3. Hsp90 and Trx-TrxR are present on synaptic vesicles and are essential to the release of active L chain in the 226 
cytosol 227 
The effect of PX-12 indicates the essential role of the Thioredoxin-Thioredoxin reductase system in 228 
reducing the interchain disulfide bond as a prerequisite for the intracellular activity of the L chain [2, 229 
50]. This redox system was previously suggested to form with Hsp90 a complex that plays an 230 
essential role in the entry of diphtheria toxin into the cytosol [42]. As the CNTs are similarly 231 
composed of a catalytic domain disulphide-linked to a subunit mediating binding and translocation, 232 
we reasoned that the two processes of disulfide reduction and cytosolic refolding may be coupled 233 
and that Hsp90 may act in concert with the Trx-TrxR system to enable the catalytic activity of the L 234 
chain in the cytosol. If this is the case, the addition at the same time of GA and of PX-12 should 235 
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produce a synergistic effect, whilst if the two systems act in a non-concerted way, the simultaneous 236 
presence of the two inhibitors should give an additive effect. This possibility was tested with the pH 237 
jump assay, in order to test the synergism of the drugs on the translocation step in a direct way. 238 
CGNs were treated with either PX-12 or GA or with their combination at concentrations, which do 239 
not cause by themselves any inhibition (2.5 µM each; Figure S5). Figure 5 shows that a very high 240 
level of inhibition is achieved in this way, strongly supporting the possibility of a concerted action of 241 
Hsp90 and TrxR-Trx in enabling the proteolytic activity of the L chain. 242 
 243 
 244 
 245 
 246 
 247 
 248 
 249 
 250 
 251 
 252 
 253 
 254 
 255 
Figure 5. PX-12 synergizes the effect of Geldanamycin in inhibiting the delivery of BoNT/D L into 256 
the cytosol. CGNs were treated like in Figure 4 with the indicated concentration of PX-12, GA, or 257 
their combination. The translocation of L was assessed by monitoring the cleavage of VAMP-2, 258 
determined via WB as a ratio to Syntaxin1A, which served as internal control, tacking the value at 259 
pH 7.4 as 100%. SD values derive from two independent experiments performed in triplicates. 260 
This result prompted us to assay for a physical interaction between Hsp90 and TrxR-Trx on synaptic 261 
vesicles, the organelle wherefrom BoNT/A translocates its L chain (Colasante et al., 2013). Figure 6A 262 
shows that rat brain synaptosomes contain both Hsp90 and Trx-TrxR and that both proteins are also 263 
present on isolated SVs. Intriguingly, the relative amount of Hsp90 increases in the fraction of 264 
docked SVs, as it is the case for Trx and TrxR [50], opening the possibility of their direct interaction 265 
on the cytosolic face of SV. Starting from crude SVs, i.e. a pool of free and docked SVs, we 266 
immunoprecipitated Hsp90 and assayed by WB for the presence of Trx and TrxR. Figure 6B shows 267 
that the three proteins physically interact and precipitate together with Rab3a which was previously 268 
reported to co-immunoprecipitate with Hsp90 [72].  269 
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 270 
Figure 6. Hsp90 interacts with TrxR-Trx system on synaptic vesicles. (A) reports the relative amount 271 
of indicated proteins contained within 10 µg of rat brain synaptosomes and their sub-fractions: 272 
PSD95 (post synaptic density protein 95), Hsp90 (Heat shock protein 90), Hsc70 (Heat shock cognate 273 
protein 70), TrxR (Thioredoxin reductase), VAMP-2 (synaptobrevin-2), Tom20 (translocase of outer 274 
membrane) and Trx1 (Thioredoxin 1). (B) Hsp90-interacting proteins were recovered by 275 
immunoprecipitation. A crude synaptic vesicles fraction was isolated from 2 mg of rat brain 276 
synaptosomes and incubated with Protein G-decorated beads coupled (or not as a control) to a 277 
monoclonal antibody specific for Hsp90. After over-night incubation at 4 °C beads were washed and 278 
Hsp90 interactors were processed for WB to assess the presence of TrxR and Trx1. The staining for 279 
Na+/K+ ATPase (Sodium-Potassium pump), Syp (synaptophysin) or Tom20 were used to exclude 280 
contaminations of plasma membrane, SVs and mitochondria respectively, Rab3a (Ras-related 281 
protein 3a) staining was used as a positive control for known interactors [72]. In the first lane (input), 282 
5 µg of crude synaptic vesicles fraction were loaded as reference. 283 
3. Discussion 284 
The results reported here are part of a large effort of this laboratory aimed at the identification 285 
of small-molecules inhibitors (SMIs) capable of preventing the neurotoxicity of BoNTs regardless of 286 
their different sequences and immunological properties [35, 73]. In fact, the growing number of 287 
BoNTs calls for an increase effort in the research of pan-inhibitors, i.e. molecules whose action does 288 
not depend on toxins specific antigenicity as it is the case of serotype-based treatments and vaccines 289 
[74, 75]. So far, research on SMIs was aimed at inhibiting the proteolysis of SNAREs, as such strategy 290 
can in principle be effective after the L chain has entered into nerve terminal cytosol. However, the 291 
recognition and binding of the L chains to their substrates requires extended interactions involving 292 
the active site and a number of exosites [23, 76-81] and this fact undermined these efforts. We 293 
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pursued a different approach based on the knowledge about the steps of the mechanism of neuron 294 
intoxication that are shared by all BoNT serotypes [2, 35].  295 
Here we show that geldanamycin, a specific inhibitor of a major heath shock protein, Hsp90, 296 
strongly prevents the activity of three prototypes of CNTs on neuronal cultures. Together with 297 
previous reports [42, 43, 45], this finding indicates that Hsp90 assists the refolding of the active 298 
chains of several bacterial exotoxins with intracellular targets that have to translocate across the 299 
membrane in an unfolded conformation.  300 
It may appear surprising that Hsp90 assists the entry of so many different toxins. However, 301 
Hsp90 is not a “folding catalyst”, i.e. it does not control the rate of protein folding in a direct way 302 
such as DPI or PPI, rather it recognizes unfolded intermediates with secondary structure avoiding 303 
their aggregation [82]. Interestingly, Hsp90 has a preference for positively charged substrates [83], 304 
making the catalytic chain of CNTs an ideal substrate during translocation, as the low pH induces L 305 
to acquire a positive charge as a result of carboxylates neutralization [22, 69, 84]. Accordingly, the 306 
interaction of Hsp90 with the three different L chain tested here, is not based, probably, on specific 307 
protein-protein interactions involving defined interfaces, instead it may be due to a hydrophobic 308 
binding activity of Hsp90 that prevents the improper folding or aggregation of the unfolded L chain 309 
emerging from the membrane in the cytosol.  310 
We also investigated the involvement other chaperons, and in particular of Hsc70, the 311 
constitutively expressed isoform of Hsp70 that together with CSP (cysteine string protein) and SGT 312 
(small glutamine-rich tetratricopeptide repeat-containing protein) takes part to a tripartite 313 
chaperone machine residing on SV [87]. However, the pharmacological inhibition of this protein did 314 
not interfere with toxin activity, underscoring the primary role of Hsp90 in CNTs entry. We believe 315 
that this choice is strictly connected to the concomitant presence of Hsp90 and the thioredoxin 316 
system on synaptic vesicles [50, 85, 86], the organelle wherefrom the L chain is expected to 317 
translocate [2], and to their physical interaction, reported here for the first time. This idea is 318 
reinforced by the second relevant finding of the present paper, i.e. the synergistic effect of GA and 319 
PX-12. This result parallel the one found at the level of early endosomes for diphtheria toxin [42] 320 
where it was shown that Hsp90 and TrxR (likely together with Trx) orchestrate a translocation 321 
complex mediating the entry of the enzymatic subunit of diphtheria toxin in the cytosol. Moreover it 322 
was recently found that Auranofin, the most potent inhibitor of TrxR identified so far, blocks the 323 
entry of diphtheria toxin, as GA does [88]. Taken together, these results suggest that DT and CNTs 324 
have evolved a mode of membrane translocation that uses the activities of Hsp90 and TrxR-Trx. We 325 
did not investigate the physiological role of this couple, however, it was previously reported that in 326 
nerve terminals Hsp90 interacts with αGDI and this interaction coordinates neurotransmitter release 327 
[89] by regulating the extraction of Rab3A from SVs [72]. Considering that the association of αGDI to 328 
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Rab proteins is strongly dependent on its redox state [90, 91], the role of Trx-TrxR redox system 329 
within the chaperone complex may be that of managing the many cysteines present on αGDI 330 
structure. 331 
4. Materials and Methods  332 
4.1 Materials  333 
BoNT/A and TeNT were purified as previously described [92, 93]. BoNT/D was produced in E. coli 334 
by recombinant methods [39, 94]. LysoTracker® Red DND-99 was purchased from Thermo Fischer 335 
Scientific (L-7528), Bafilomycin A1 (sc-201550) and PX-12 (sc-358518) from Santa Cruz 336 
Biotechnology, Cytosine β-D-arabinofuranoside hydrochloride (C6645), DNAse I (DN25), 337 
poly-L-lysine hydrobromide (P1274), Cyclosporin A (30024) and VER-155008 (SML0271) from Sigma 338 
Aldrich. Geldanamycin (GA) was purchased from Santa Cruz (sc-200617) and to prevent loss of 339 
activity, a fresh stock solution of 12.5 mM in DMSO was prepared for each experiment. Syntaxin 1A 340 
(110 111), VAMP-2 (104 211) and Rab3a (107 111) antibodies were purchased from Synaptic System. 341 
Anti-synaptophysin (clone Sy38) was from Dako, anti-thioredoxin reductase 1 (07-613) was from 342 
Merck Millipore, anti-thioredoxin 1 (clone EPR6111) was from GeneTex, anti-PSD95 (P-246) was 343 
from Sigma Aldrich, anti-Hsp90 (610418) was from BD Biosciences, anti-tom20 (Fl-145) was from 344 
Santa Cruz. SNAP-25 (SMI81,ab24737), Na+/K+ ATPase (ab7671) antibodies were purchased from 345 
Abcam. The antibody specific for SNAP-25A (SNAP-251-197) was produced in our laboratory and used 346 
as previously reported [70]. Secondary antibody were from Merk Millipore (HRP-conjugated) and 347 
from Life Technologies (Alexa Fluor-conjugated). 348 
The pyrrolidine-substituted acridizinium derivative (compound 2) has been synthesized as 349 
described in the literature [95, 96] purified by preparative HPLC (purity > 98 %) and fully 350 
characterized by 1H-NMR, 13C-NMR and HRMS. 351 
4.2. Cerebellar Granule Neurons (CGNs) cultures and botulinum neurotoxin inhibition assay 352 
Primary cultures of rat cerebellar granule neurons (CGNs) were prepared from 6- to 8-days-old rats 353 
[97]. Cerebella were isolated, mechanically disrupted and then trypsinized in the presence of DNAse 354 
I. Cells were then plated into 24 well plates, pre-coated with poly-L-lysine (50 μg/mL), at a cell 355 
density of 3.5 x 105 cells per well. Cultures were maintained at 37 °C, 5% CO2, 95% humidity in BME 356 
supplemented with 10% fetal bovine serum, 25 mM KCl, 2 mM glutamine and 50 μg/mL gentamicin 357 
(complete culture medium). To arrest growth of non-neuronal cells, cytosine arabinoside (10 μM) 358 
was added to the medium 18–24 h after plating. CGNs at 6-8 days in vitro were treated for 30 min 359 
with the indicated concentration of GA in complete culture medium at 37 °C and 5% CO2. 360 
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Thereafter, 2.5 nM BoNT/A or 0.5 nM TeNT in complete medium was added and left for 3.5 hours at 361 
37 °C and 5% CO2. In the case of BoNT/D, owing to its potency, the toxin was added as pulse of 15 362 
minutes at a concentration of 0.01 nM. The neuronal culture was then washed and the culture 363 
medium with the same concentration of inhibitor was restored for 195 min.  364 
4.3. Immunoblotting and immunocytochemistry 365 
For immunoblotting analysis, cells were directly lysed with reducing Laemmli sample buffer 366 
containing protease inhibitors (complete Mini EDTA-free, Roche). Equal amounts of protein were 367 
loaded onto a 4-12% NuPage gel or 12% NuPage gel (Life technologies) and separated by 368 
electrophoresis in MES or MOPS buffer (Life technologies), respectively. Proteins were then 369 
transferred onto Protran nitrocellulose membranes (Whatman) and saturated for 1 h in PBST (PBS 370 
0.1% Tween20) supplemented with 5% non-fatty milk. Incubation with primary antibodies was 371 
performed overnight at 4°C. The membranes were then washed three times with PBST and 372 
incubated with secondary HRP-conjugated antibodies. Finally, membranes were washed three times 373 
with PBST and twice with PBS. Visualization was carried out using Luminata Crescendo (Merck 374 
Millipore).  375 
For immunocytochemistry analysis, after the treatment, CGNs were washed with PBS, fixed for 10 376 
minutes at RT with 4% paraformaldehyde in PBS, quenched (50 mM NH4Cl in PBS) for 20 minutes 377 
and permeabilized with 5% acetic acid in ethanol for 20 minutes at -20 °C. BoNT/A cleavage was 378 
evaluated following the generation of SNAP-25A, whereas the cleavage of TeNT and BoNT/D was 379 
evaluated with an antibody recognizing the full-length form of VAMP-2. Primary antibodies were 380 
detected with secondary Alexa Fluor-conjugated antibodies. Coverslips were mounted using 381 
Fluorescent Mounting Medium (Dako, S3023) and examined by epifluorescence (Leica CTR6000) 382 
microscopy.  383 
4.4. cpV-HC/A binding and internalization assay 384 
The HC of BoNT/A (nucleotides corresponding to 876-1296) with a N-terminal fused with cpV 385 
(Circularly Permutated Venus) at the N-terminus was cloned into a pET28a His-tag vector 386 
(Novagen) and expressed into BL21 (DE3) E. coli cells. Protein purification was carried out by affinity 387 
chromatography with a prepacked HisTrap Ni column (GE Healthcare) and then by size-exclusion 388 
chromatography using a Superdex 200, 10/300GL column (GE Healthcare). Purified HC/A was 389 
dialyzed into 20 mM TRIS, 200 mM NaCl, 40% glycerol (pH 7.6). For the assay, CGNs were treated 390 
with GA 12.5 μM or vehicle (DMSO) in culture medium at 37 °C. After 30 minutes, 250 nM 391 
cpV-HC/A was added and the concentration of KCl increased at 57 mM. After 30 min, neurons were 392 
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washed twice with PBS, lysed and immunoblotted. cpV-HC/A was detected with an anti-GFP 393 
antibody (Cell Signaling, #2956). 394 
4.5. Synaptic vesicles dynamics assay 395 
Experiment was performed as previously described [62]. CGNs were treated with vehicle (DMSO) 396 
or 12.5 μM of GA or 10 nM BoNT/D for 30 min at 37 °C. 5 μg/ml of an anti Synaptotagmin-1 antibody 397 
(recognizing the lumenal domain of the protein, Synaptic System, 105-101) was added, with the 398 
concentration of KCl adjusted to 57 mM. After 30 minutes, CGNs were lysed in non-reducing 399 
condition and processed for WB. Membrane was then saturated for 1 hour in PBST supplemented 400 
with 5% non-fatty milk and directly incubated with secondary antibody.  401 
4.6. Maturation of acidic compartment assay 402 
CGNs at 6–8 DIV were treated for 30 min with vehicle (DMSO) or 12.5 μM GA or 10 nM bafilomycin 403 
A1 in complete culture medium supplemented with 6.25 mM HEPES at 37 °C and 5% CO2. 75 nM 404 
Lysotracker® Red DND-99 was added for 60 minutes. Cells were then washed with Krebs-Ringer 405 
buffer (KRH: 128 mM NaCl, 2.5 mM HEPES, 4.8 mM KCl, 1.3 mM CaCl2, 1.2 mM MgSO4 and 1.2 mM  406 
K2HPO4) and images of living neurons were acquired with a Leica CTR6000 microscope.  407 
4.7. In vitro proteolytic activity 408 
0.1 μg BoNT/D or BoNT/A or TeNT was incubated in reducing buffer (150 mM NaCl, 10 mM 409 
NaH2PO4, 15 mM DTT pH 7.4) in the presence of 12.5 μM GA for 30 min at 37 °C or vehicle (DMSO). 410 
Then 1 μg of recombinant GST-VAMP-2 (1-96), for BoNT/D or TeNT, or 1 μg of recombinant 411 
GST-SNAP-25, for BoNT/A, was added to the reduced toxins, the concentration of inhibitor or 412 
vehicle was restored, and the reaction was carried out for 4 hours at 37 °C. VAMP-2 cleavage was 413 
assessed by SDS-PAGE. 414 
4.8. Low pH induced translocation of BoNT/D across the plasma membrane  415 
CGNs at 6–8 DIV were treated with vehicle (DMSO) of different concentrations of GA or PX-12, or 416 
their combination for 30 min at 37 °C, 5% CO2. Neurons were washed twice with cold culture 417 
medium and subsequently incubated with 200 pM of BoNT/D in ice-cooled medium (pH 7.4) and 418 
left at 4 °C for 15 minutes. After washing twice with the same cold medium, pre-warmed (37 °C) 419 
medium A (123 mM NaCl, 6 mM KCl, 0.8 mM MgCl2, 1.5 mM CaCl2, 5 mM NaPi, 5 mM citric acid, 420 
5.6 mM glucose, 10 mM NH4Cl), adjusted at pH 7.4 or 4.5, was added for 10 minutes in the presence 421 
of vehicle or of inhibitors (alone or in combination). Cells where then washed twice and further 422 
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incubated, for 185 minutes, in normal culture medium (pH 7.4) supplemented with 50 nM 423 
Bafilomycin A1 and containing inhibitors.  424 
4.9. Purification of synaptic vesicles and immunoprecipitation 425 
Synaptosomes and synaptic vesicles were isolated from cerebral cortices as previously described 426 
[50], with minor changes of the classical procedure [98]. Namely, after differential centrifugations, 427 
crude synaptic vesicles were separated through a continuous sucrose gradient (0.25-1.5 M sucrose, 4 428 
mM HEPES, pH 7.3) in a Beckmann XL-80 ultracentrifuge for 5 hr with a SW28 rotor. Vesicles 429 
sedimenting at about 300-400 mM sucrose (free SV) and those sedimenting at 800-1000 mM (docked 430 
SV) were collected and pelleted by centrifugation in a 70Ti rotor. These vesicle fractions were 431 
re-suspended in SV buffer (4 mM HEPES, 300 mM glycine, pH 7.4 supplemented with complete 432 
protease inhibitors, EDTA-free). For immunoblotting analysis, protein concentration was 433 
determined with BCA test (Pierce BCA protein assay, Thermo Scientific) and 10 µg of different 434 
fractions were used for SDS-PAGE under reducing conditions.  435 
Immunoprecipitation of Hsp90 was carried out as previously reported [99]: 2 mg of rat brain 436 
synaptosomes were re-suspended in buffer B (20 mM HEPES, 140 mM NaCl, 5 mM KCl, 5 mM 437 
NaHCO3, 1.2 mM Na2HPO4, 1 mM MgCl2 and 10 mM glucose, pH 7.4) and subjected to osmotic 438 
shock using H2O in presence of protease inhibitors for 30 minutes at 4 °C. Sample were subjected to 439 
three passages though 18 G needles and three through 27 G needles and then centrifuged for 5 min 440 
at 10000 g. The resulting supernatant was centrifuged for 1 hour at 80000 r.p.m. to yield a crude 441 
synaptic vesicle fraction in the pellet and a cytosolic fraction in the supernatant [100]. The pellet 442 
fraction was re-suspended in buffer B and incubated overnight at 4 °C with G protein-decorated 443 
Dynabeads (Life Technology) coupled to anti-Hsp90 antibody, preventively washed in PBS 0.1% 444 
BSA. Beads were then extensively washed twice with a buffer containing 20 mM TRIS, 80 mM NaCl 445 
and 1% Triton X-100, pH 7.4 and twice with PBS. Hsp90 interactors were eluted by addition of 0.2 M 446 
glycine (pH 2.6). Samples were then added to non-reducing loaded sample buffer and subjected to 447 
SDS-PAGE. Proteins were then labeled with specific antibodies.  448 
4.10. Viability test  449 
CGNs were seeded in a 96 wells plates at a cell density 105 cells per well. After 6 div, different 450 
concentration of GA, ranging from 0 to 20 μM, were added and left for 4 hours. Neurons were then 451 
washed and CellTiter 96® AQueous (Promega) performed according to manufacturer indication.  452 
Supplementary Materials: The following are available online at www.mdpi.com/link, Figure S1: title, Table S1: 453 
title, Video S1: title. 454 
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 455 
Figure S1. Hsp90 inhibition prevents BoNT/A-mediated cleavage of SNAP-25 in CGNs. Experiment 456 
was conducted as in Figure 1, thereafter, neurons were lysed and SNAP-25 cleavage was estimated 457 
with an antibody that recognizes both the intact and truncated form; Syntaxin 1A and VAMP2 were 458 
used as loading control. A typical immunoblot is reported (NC, only vehicle; PC, only BoNT/A; the 459 
six following lanes refer to samples pretreated with different GA concentrations: 12.5, 10, 7.5, 5, 2.5, 1 460 
µM). 461 
 462 
Figure S2. Neuron viability upon geldanamycin treatment. CGNs were treated with increasing 463 
concentration of geldanamycin ranging from 2.5 to 20 µM or vehicle (DMSO) in culture medium 37 464 
°C for 4 hours. Cell viability was then assayed with a MTS assay. Data are presented as a percentage 465 
with respect to non-treated cells. All data are presented as mean values and error bars indicate the 466 
deviation standard obtained from two independent experiments. 467 
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 468 
Figure S3. Cyclosporine A, VER-155008 and compound-2 does not prevent BoNT/A intoxication in 469 
CGNs. Neurons were treated like in Figure 1 but using different inhibitors: (A) cyslosporine A, (B) 470 
VER-155008 or (C) compound-2. Thereafter, CGNs were lysed and immunoblotted staining with 471 
anti-SNARE antibodies. Typical WB are shown. NC, only vehicle; PC, only BoNT/A; the six 472 
following lanes refer to samples treated with toxin plus different inhibitor concentrations: 50, 40, 30, 473 
20, 10, 5 µM for CsA and VER-155008; 5, 2.5, 1, 0.5, 0.25, 0.1 µM for compound-2.  474 
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 475 
Figure S4. Geldanamycin does not affect synaptic vesicles dynamics. (B) CGNs were treated as in 476 
Figure 3A but using as reporter of SVs dynamics an antibody against the lumenal domain of 477 
Synaptotagmin-1. Where indicated, BoNT/D was added before starting GA treatment. The 478 
internalized antibody was detected by WB, using directly a secondary antibody. Syntaxin 1A and 479 
SNAP-25 were considered as loading controls, instead, VAMP-2 staining was used to assess BoNT/D 480 
cleavage. In the first lane (input) 50 ng of the anti-Synaptotagmin 1 antibody were loaded as 481 
reference. The immunoblot is representative of three independent sets of experiments. 482 
 483 
Figure S5. PX-12 and geldanamycin inhibit the translocation of BoNT/D L chain across the plasma 484 
membrane in a concentration dependent manner. CGNs were like in Figure 4 using the indicated 485 
concentrations of PX-12 (A) or GA (B). The translocation of BoNT/D was assessed by monitoring the 486 
cleavage of VAMP-2, determined via WB (top panels). Bottom panels show the amount of intact 487 
VAMP-2 reported as a ratio to Syntaxin 1A which served as loading control, taking the value in pH 488 
7.4 treated-cells as 100%. All data are presented as mean values with SD values arising from three 489 
independent experiments. 490 
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